Adjuvant TKI Use in High-Risk Clear Cell RCC Not Effective
Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.
FDA Warns of Rare Cancer Linked to Breast Implants
The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery.
ASCO Statement Opposes Trump’s Recommended Budget Cuts to NIH
ASCO has released a statement announcing its opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health.
Novel Calculator Guides Treatment Choice in Esophageal Cancer
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices.
Short-Course RT With Delayed Surgery Viable in Rectal Cancer
No difference in time to recurrence, recurrence-free survival, or overall survival were noted for patients with rectal cancer who underwent one of three different preoperative radiotherapy regimens.
Combined Immunotherapy, Thoracic RT Carries Moderate Toxicity in Lung Cancer
A study of the combination of radiation therapy and immune checkpoint inhibitors for the treatment of advanced lung cancer found a modest risk of side effects.
‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.
By clicking Accept, you agree to become a member of the UBM Medica Community.